Characterization of a thymidylate synthase (TS)-inducible cell line: A model system for studying sensitivity to TS- and non-TS-targeted chemotherapies

Clinical Cancer Research

Volumn 7, Issue 11, 2001, Pages 3533-3539

  Longley, D B ^a   Ferguson, P R ^a   Boyer, J ^a   Latif, T ^a   Lynch, M ^a   Maxwell, P ^a   Harkin, D P ^a   Johnston, P G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN E; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLIC ACID ANTAGONIST; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INDUCTION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CAMPTOTHECIN; CDC2-CDC28 KINASES; CELL CYCLE; CELL DIVISION; CISPLATIN; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; FOLIC ACID ANTAGONISTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RNA, MESSENGER; TETRACYCLINE; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0035176182     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Thymidylate synthase - A target enzyme in cancer chemotherapy
2. Fluorinated pyrimidines
3. Antimetabolites
4. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells
5. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor growth in vitro and in vivo: A new agent for clinical study
6. ZD 1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer
7. Effects of folate receptor expression following stable transfection into wild-type and methotrexate transport-deficient ZR-75-1 human breast cancer cells
8. Substrate-specificity of mammalian folypolyglutamate synthase for 5,10-dideazatetrahydrofolate analogs
9. Cellular pharmacology and in vivo activity of a new anticancer agent ZD9331: A water soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
10. LY231514, a pyrrolo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes
11. Some determinants of response to folate-based thymidylate synthase inhibitors in human colon and ovarian tumour cell lines
12. Increased levels of thymidylate synthase in cells exposed to 5-fluorouracil
13. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS106 in 5-fluorouracil sensitive and resistant human cancer cell lines
14. Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer
15. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
16. Resistance to Tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines
17. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon γ
18. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase
19. The thymidylate synthase inhibitor ICI D1694 overcomes translational detainment of the enzyme
20. Identification of an RNA binding site for human thymidylate synthase
21. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro
22. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex
23. Structural and functional analysis of the human thymidylate synthase gene
24. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
25. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1
26. 4
27. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition
28. Mechanism of action of antitumour platinum compounds
29. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin
30. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport and cell death
31. 1 phase progression: Cycling on cue
32. 1 phase of the human cell cycle
33. 1-to-S phase transition
34. Cyclin A is required at two points in the human cell cycle
35. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
36. A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle
37. Regulation of p53 expression by thymidylate synthase